Motivation: Hypoglycemia is a serious medical condition commonly occurring in patients with Type 1 Diabetes (T1D). The risk of severe hypoglycemia  increases markedly with the increasing duration of the disease and is a major burden for patients and their families.
Lead Program(s): TTP399 is a novel, oral, small molecule, liver selective glucokinase activator being developed under breakthrough therapy status granted by the FDA as an adjunct therapy to insulin in patients with T1D. TTP399 recently completed a phase 2 study in patients with T1D demonstrating 40% reduction in hypoglycemic events compared to placebo and allowed for tighter long term glycemic control.
 Frier BM. The incidence and impact of hypoglycemia in type 1 and type 2 diabetes. International Diabetes Monitor 2009;21:210–218